Format

Send to

Choose Destination
Cancer. 2019 May 1;125(9):1410-1413. doi: 10.1002/cncr.32042. Epub 2019 Mar 12.

Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?

Author information

1
Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
2
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
3
Clinic of Laboratory Medicine, St Olav's Hospital, Trondheim, Norway.

KEYWORDS:

AML; acute myeloid leukemia; bone marrow; immune checkpoint blockade; immunotherapy

PMID:
30861094
PMCID:
PMC6467744
[Available on 2020-05-01]
DOI:
10.1002/cncr.32042

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center